Dihexa is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Severe renal impairment (estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2) Known hypersensitivity to metformin Acute or chronic metabolic acidosis, including diabetic ketoacidosis (from uncontrolled diabetes), with or without coma
Nicotine replacement therapy (NRT) products, including gums, patches, and lozenges, deliver the compound in slower, lower doses that are less addictive and are used medically to help people quit smoking. Synthetic derivatives of nicotine, such as varenicline, act as partial agonists at nicotinic receptors and are also used as smoking cessation aids. Nicotine itself is not classified as a carcinogen by either the International Agency for Research on Cancer or the Surgeon General of the United States. At high doses it can cause nicotine poisoning and respiratory paralysis. Nicotine is also a known teratogen, associated with adverse developmental effects during pregnancy, and may impair adolescent neurodevelopment, though the extent of this effect in humans remains debated.
Translational Research: The Journal of Laboratory and Clinical Medicine is a monthly peer-reviewed medical journal covering translational research. It was established in 1915 as The Journal of Laboratory and Clinical Medicine obtaining its current title in 2006. Jeffrey Laurence (Weill Cornell Medical College) has been editor-in-chief since 2006. He was preceded by Dale Hammerschmidt. It is the official journal of the Central Society for Clinical and Translational Research. It is published by Mosby.
Sources: en.wikipedia.org
=== Influence of temperature, relative humidity and rate of air circulation === The external drying conditions (temperature, relative humidity and air velocity) control the external boundary conditions for drying, and hence the drying rate, as well as affecting the rate of internal moisture movement. The drying rate is affected by external drying conditions, as will now be described.
The liquid containing the analytes of interest (typically 10−6 - 10−4 M needed ) is dispersed by electrospray, into a fine aerosol. Because the ion formation involves extensive solvent evaporation (also termed desolvation), the typical solvents for electrospray ionization are prepared by mixing water with volatile organic compounds (e.g. methanol acetonitrile). To decrease the initial droplet size, compounds that increase the conductivity (e.g. acetic acid) are customarily added to the solution. These species also act to provide a source of protons to facilitate the ionization process. Large-flow electrosprays can benefit from nebulization of a heated inert gas such as nitrogen or carbon dioxide in addition to the high temperature of the ESI source. The aerosol is sampled into the first vacuum stage of a mass spectrometer through a capillary carrying a potential difference of approximately 3000 V, which can be heated to aid further solvent evaporation from the charged droplets. The solvent evaporates from a charged droplet until it becomes unstable upon reaching its Rayleigh limit. At this point, the droplet deforms as the electrostatic repulsion of like charges, in an ever-decreasing droplet size, becomes more powerful than the surface tension holding the droplet together. At this point the droplet undergoes Coulomb fission, whereby the original droplet 'explodes' creating many smaller, more stable droplets. The new droplets undergo desolvation and subsequently further Coulomb fissions.
Unlike many other hormones, adrenaline (as with other catecholamines) does not exert negative feedback to down-regulate its own synthesis. Abnormal adrenaline levels can occur in various conditions, such as surreptitious adrenaline administration, pheochromocytoma, and other tumors of the sympathetic ganglia. Its action is terminated with reuptake into nerve terminal endings, some minute dilution, and metabolism by monoamine oxidase and catechol-O-methyl transferase into 3,4-Dihydroxymandelic acid and Metanephrine.
== Diagnosis == Most patients with drug-induced QT prolongation are asymptomatic and are diagnosed solely by EKG in association with a history of using medications known to cause QT prolongation. A minority of patients are symptomatic and typically present with one or more signs of arrhythmia, such as lightheadedness, syncope, or palpitations. If the arrhythmia persists, patients may experience sudden cardiac arrest.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.